Category Archives: Uncategorized

15Jul/19
IASO Compilation-700x400

More Than Skin Deep: Dassault Systèmes is Transforming the Patient Experience

Dassault Systèmes 3DExperience North America 2019 Forum Event Brief

By: Daniel R. Matlis, President

At this year’s 3DEXPERIENCE North America Forum, Dassault Systèmes continued to demonstrate its commitment to transforming the patient experience.

Under the leadership of Bernard Charlès, Vice Chairman, Chief Executive Officer, the company continues to substantially deliver on the promise: “to enable innovative patient experiences through a Holistic Patient-Centric strategy.”  (Read:  Dassault Targets Life-Sciences with Mind, Body and Soul)

According to Charlès there are several concurrent themes that are impacting the Life Science industry with Bioscience playing a major role.

  • Healthcare is expensive
  • Healthcare needs to be more inclusive
  • Life-Science product development needs to take advantage of technological changes

“Dassault Systèmes is investing massively in Life Sciences to transform the patient experience with a culture of sustainable innovation and the use of cutting edge technology,” added Charles.

At the 3DExperience Forum, the company once again delivered on their vision with the introduction of IASO, an oncology treatment concept that contains a removable patch that attaches to the patient’s skin to deliver a biologic solution, dosed through a connected, wearable and reusable device.  IASO aims to showcase how Dassault Systèmes 3DEXPERIENCE platform enables its customers to transform the patient experience with innovative solutions that combine many technologies to safely shift the point of care from the clinic…to the patient’s home.

Download a PDF of the complete Event Brief

14Jun/18
QAD-Explore-2018-1

Thriving in a World Where the Only Certainty is UNCERTAINTY

By Daniel R. Matlis, President

“The only certainty is UNCERTAINTY” declared Anton Chilton, QAD’s Chief of Global Field Operations, during his opening remarks at QAD Explore 2018 in Dallas last month.

“The pace of change is accelerating and if you can’t keep up, you’ll struggle to survive,” said Carter Lloyds, QAD’s Chief Marketing Officer.

QAD-Explore-2018-1

To keep up with the accelerating rate of change and cope with uncertainty, organizations must become an “agile and effective enterprise” was a key theme at QAD Explore 2018.

Continue reading

30Apr/18
Jumping

Change is a Constant, Why is it So Challenging…

By: Tamara Briggs, Process Improvement Analyst

History has taught us that the only constant is change, however in today’s industries, the rate of change is happening at an increasingly, unmanageable rate.  Axendia’s research on the future of change and configuration management revealed that over 50% of industry professionals worry that their current processes are too slow and cumbersome.

Daniel Matlis, President of Axendia, and Mike Jovanis, Vice President of Vault Quality at Veeva Systems, shared their perspectives on the challenges of change management in FDA regulated industries during an FDANews Webinar.  Specifically, they discussed the importance of simplifying change management across the product life cycle.  Topics of discussion included:

  • Change Management Challenges
  • Closed-loop Quality Processes
  • Collaborating on Change Management
  • Moving from Documents to Structured Data
  • Becoming a Proactive Quality Organization
  • Transforming Change Management Programs

Continue reading

27Apr/18
Patient

Lot Size: YOU – When YOU are the RAW MATERIAL and the FINISHED PRODUCT

Managing the Chain of Custody and Identity for Regenerative Medicine Products.

By: Daniel R. Matlis, President

According to FDA Commissioner Scott Gottlieb, M.D.  “We’re at the beginning of a paradigm change in medicine with the promise of being able to facilitate regeneration of parts of the human body, where cells and tissues can be engineered to grow healthy, functional organs to replace diseased ones; new genes can be introduced into the body to combat disease; and adult stem cells can generate replacements for cells that are lost to injury or disease. This is no longer the stuff of science fiction. This is the practical promise of modern applications of regenerative medicine.”

The promise of individualized therapies is why the FDA is encouraging and supporting innovation in this field. To this end, the Agency has released a framework outlining how it intends to apply existing laws and regulations to oversee these products. FDA’s stated goal is to ensure that it is nimble and creative to foster innovation, while taking steps to protect the safety of patients.

In individualized patient-derived cellular gene therapy products, the patient is the raw material, product, and the treatment.  In gene therapy products, cells removed from the patient become the raw material.  They are then genetically modified and returned to the patient as the “finished product”.

Continue reading

11Jan/18
2017 Year end review

Award Winning Year for Axendia – Looking at the 2018 Crystal Ball

By Daniel R. Matlis

2017 has been an exceptional year for Axendia.  We were recognized by CIOReview magazine as one of the 20 Most Promising Pharma and Life Sciences Solution Providers.  We also had the opportunity to address audiences around the globe, including Asia, Europe, North and South America.

Our analysts had the privilege to provide insight and trusted advice to leaders across the Life Science and Healthcare ecosystems including executives in industry, technology & service providers as well as policy makers and regulators.
In the last year we advised our clients on critical topics such as: